Alessandro D’Angelo

Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study

Orazio Caffo, Ugo De Giorgi, Lucia Fratino et al. · European Urology · 2014 · 83 citations · Full text

Medicine, Oncology, Urology +12

High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)

Stefano Cascinu, Mario Scartozzi, Roberto Labianca et al. · British Journal of Cancer · 2004 · 69 citations · Full text

Medicine, Oncology, Surgery +17

Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme

Francesca Maines, Orazio Caffo, Ugo De Giorgi et al. · Clinical Genitourinary Cancer · 2015 · 21 citations

Medicine, Oncology, Pharmacology +16

Impact of Visceral Metastases on Outcome to Abiraterone After Docetaxel in Castration-Resistant Prostate Cancer Patients

Vincenza Conteduca, Orazio Caffo, Lucia Fratino et al. · Future Oncology · 2015 · 19 citations

Medicine, Oncology, Pharmacotherapy +17

Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the <scp>I</scp> talian Named Patient Programme

Orazio Caffo, Ugo De Giorgi, Lucia Fratino et al. · British Journal of Urology · 2014 · 19 citations

Medicine, Oncology, Pharmacotherapy +17